Health 2.0 Europe: Over 35 Speakers from 15 Countries Already Confirmed

27 - 28 October 2011, Berlin, Germany.
Following the success of our first event in Paris in April 2010, the 2nd annual Health 2.0 Europe to hip Berlin. The 2010 event gathered over 500 delegates in its first year and showcased the best of Europe's Health 2.0 offering. The 2nd edition will reconvene all the leaders and stakeholders in web 2.0 for health: IT solution providers, health professionals, patient organizations, health authorities, public and private insurance organizations, medical devices and pharmaceutical companies, telecom groups, VC and financiers, policy makers, academics and more...

Health investor Esther Dyson to present on 'From Health to Wellness 2.0'
An active investor in technology start-ups with a keen interest in the potential of internet technology to change healthcare, Esther Dyson from EDventure Holdings will present on 'From Health to Wellness 2.0'. Her health technology investments include Medstory, sold to Microsoft in 2007, 23andMe, Habit Labs, Medscape, OrganizedWisdom, PatientsLikeMe and ReliefInsite.

Over 35 speakers already confirmed
Confirmed speakers also include:

  • Roberto ASCIONE, Publicis Healthware International, Italy
  • Alberto SANNA, Fondazione Centro San Raffaele, Italy
  • Gábor GYARMATI, Szinapszis Group, Hungary
  • Anna GYARMATI, KamaszPanasz, Hungary
  • Emma STANTON, Department of Health, UK
  • Chris COOPER, EPG Health Media, UK
  • Matt JAMESON EVANS, HealthUnlocked, UK
  • Tim RINGROSE, Networks in Health/Doctors.net.uk, UK,
  • Howard LAST, Active Medicine Ltd, UK
  • Jonathan BLOOR, DocCom, UK
  • Anatole MENON-JOHANSSON, SXT Health CIC, UK
  • Frank ANTWERPES, DocCheck, Germany
  • Michael ALVERS, Transinsight GmbH, Germany
  • Britta LANG, Cochrane Collaboration, Germany
  • Jorge Juan FERNANDEZ, Hospital Sant Joan de Déu, Spain
  • Frederic LLORDACHS, Doctoralia, Spain
  • Miguel CABRER, Medting, Spain
  • Bartho HENGST, KWF Kankerbestrijding, The Netherlands
  • René SIELHORST, Intenz, The Netherlands
  • Joris MOOLENAAR, IPPZ, The Netherlands
  • Robert HALKES, Drimpy, The Netherlands
  • Jasper TEN DAM, my Jellinek, The Netherlands
  • Marco VITULA, Diagnosia, Austria
  • Stephen COOK, 23 Gears Web Systems, Sweden
  • Anna OMSTEDT LINDGREN, MedUniverse, Sweden
  • Greg BIGGERS, Genomera, US
  • Pablo GRAIVER, TrialReach, UK/Israel
  • Dennis VAN ROOIJ, medCrowd, UK/The Netherlands
  • Laurent COUSSIRAT, The Mood Institute, France
  • Ulrich SCHULZE-ALTHOFF, Medisana Space Technologies GmbH, Germany
  • Roman SCHENK, Protegia GmbH, Germany
  • Rachel IREDALE, Cancer Genetics Story Bank, UK
  • Wouter TUIL, MijnZorgnet, NL
  • Roman RITTWEGER, Advisors in Healthcare
  • David Clifford, PatientsLikeMe, USA
  • Kai Sostmann, Charité University Hospital, Germany
  • Topi Hanhela, Pharmaceutical Information Centre, Finland

For further information and registration, please visit:
http://www.health2con.com/europe/

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...